Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael Clynes

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Blood Advances|August 30, 2023
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemiaFarhad Ravandi, Asad Bashey, James Foran, et al.
Breast Cancer Research : BCR|June 15, 2018
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancerNadine Norton, Nicholas Fox, Christie-Ann McCarl, et al.
Journal for Immunotherapy of Cancer|January 21, 2016
Novel technologies and emerging biomarkers for personalized cancer immunotherapyJianda Yuan, Priti S Hegde, Raphael Clynes, et al.
Nature Communications|January 23, 2015
Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility lociRegina C Betz, Lynn Petukhova, Stephan Ripke, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Blood Advances|August 30, 2023
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemiaFarhad Ravandi, Asad Bashey, James Foran, et al.
Breast Cancer Research : BCR|June 15, 2018
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancerNadine Norton, Nicholas Fox, Christie-Ann McCarl, et al.
Journal for Immunotherapy of Cancer|January 21, 2016
Novel technologies and emerging biomarkers for personalized cancer immunotherapyJianda Yuan, Priti S Hegde, Raphael Clynes, et al.
Nature Communications|January 23, 2015
Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility lociRegina C Betz, Lynn Petukhova, Stephan Ripke, et al.
Pageof 5